• Puromycin Aminonucleoside: From Injury Model to Insight

  2026-09-04

  A translational perspective on how puromycin aminonucleoside connects podocyte biology, nephrotic injury modeling, and emerging insoluble-proteome workflows while defining practical limits for renal research.

• YM 58483 (BTP2): Mapping SOCE Causality

  2026-09-03

  YM 58483 (BTP2) is a powerful pharmacological tool for testing how store-operated calcium entry connects cellular stimulation with immune transcription and tissue fibrosis. This article presents an assay-interpretation framework that distinguishes pathway dependence from channel identity, using recent ORAI2–NFAT1 findings as a practical case study.

• Prostaglandin E2: From Metabolomics to Mechanism

  2026-09-03

  Explore how Prostaglandin E2 can convert metabolomics observations into testable receptor-level hypotheses for inflammation research and cardiovascular biology. This guide combines PGE2 pharmacology, analytical strategy, assay design, and practical reagent handling.

• DiscoveryProbe Bioactive Compound Library Plus Workflow

  2026-09-02

  Translate a 5,072-compound bioactive collection into a staged workflow for ligand discovery, pathway profiling, and target validation. This guide combines thermal shift assay logic with orthogonal biochemical and cellular readouts, helping researchers distinguish genuine binders from assay artifacts in cancer, protease, and signaling studies.

• HyperScript First-Strand cDNA Synthesis Kit for SCI

  2026-09-02

  Translate spinal cord injury pathway findings into a practical RT-qPCR workflow with stronger support for low-abundance and structurally complex RNA. This guide shows how primer choice, thermal optimization, and controls can improve measurements of HIF1A, HMOX1, GPX4, and SLC7A11.

• MDL 28170: A Selective Calpain Inhibitor Workflow

  2026-09-01

  MDL 28170 combines cell permeability, brain exposure, and nanomolar cysteine-protease inhibition for neuroprotection research, apoptosis assay development, and injury-model validation. This practical guide translates recent BDNF/TrkB findings into controllable workflows while addressing solubility, target attribution, and assay reproducibility.

• Anti-ROR1 Antibody: Applied Zilovertamab Workflows

  2026-09-01

  Build reproducible ROR1 binding, cell-surface, and signaling assays with Zilovertamab while keeping target specificity separate from nonspecific stress responses. This guide combines practical ELISA, FACS, functional, and animal-model planning with a cautious translation of recent liver-injury findings.

• AS1842856: Foxo1 Inhibition for Assay Design

  2026-08-31

  AS1842856 is a Foxo1 inhibitor that enables direct, activity-level interrogation of gluconeogenesis, autophagy, and PI3K–Akt–Foxo1 signaling. This guide translates its biochemical profile into better controls, assay decisions, and carefully bounded applications in metabolic and mesenchymal stem cell research.

• Leptin (116-130), amide, mouse: Assay Guide

  2026-08-30

  Build more controlled metabolic and immunometabolic assays with a defined, amidated mouse leptin fragment rather than relying only on complex in vivo models. This guide covers reconstitution, dose-finding, orthogonal readouts, troubleshooting, and responsible translation of findings from obesity and diabetes research.

• Cytarabine as a Precision Cell-Death Probe

  2026-08-29

  Cytarabine and AraC can do more than model leukemia treatment: they provide a controlled DNA-replication-stress comparator for separating apoptosis from necroptosis. This article connects Cytarabine mechanism, resistance biology, and the RIPK3-degradation findings of a landmark viral-immunity study to improve assay interpretation.

• Luminescent ATP Cell Viability Assay Kit I

  2026-08-29

  The Luminescent ATP Cell Viability Assay Kit I connects luciferase luminescence detection with mechanism-aware ferroptosis research. Learn how ATP-based cell viability measurement can clarify ciprofloxacin–RSL3 responses while avoiding common interpretation errors.

• 3-Aminobenzamide (PARP-IN-1) Research Guide

  2026-08-28

  3-Aminobenzamide, also called PARP-IN-1, is a research PARP inhibitor with a product-reported IC50 of approximately 50 nM in CHO cells. It supports controlled studies of oxidative stress, endothelial signaling, diabetic nephropathy, and PARP-linked innate immunity, but model-specific validation remains essential.

• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-08-28

  The reference study combines phenotypic small-molecule screening with a TAM-avid nanoconstruct to suppress SPP1 in tumor-associated macrophages. Its lead formulation, CANDI460, reduced SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, establishing a preclinical strategy for myeloid-cell-directed cancer therapy.

• Tivozanib (AV-951): Translating VEGFR Precision

  2026-08-27

  Tivozanib (AV-951) offers a selective way to interrogate VEGFR1–3 biology, but translational value depends on measuring more than aggregate viability. This article connects target pharmacology with response kinetics, assay design, renal cell carcinoma treatment research, and strategic benchmarking for anti-angiogenic therapy programs.

• miR-196a, c-Myc, and EAC Aggressiveness

  2026-08-27

  The reference study identifies miR-196a as a functional driver of esophageal adenocarcinoma aggressiveness, rather than only a progression-associated biomarker. Its experiments connect miR-196a to coordinated activation of the c-MYC/TERT/NFκB axis, epithelial-to-mesenchymal transition, and increased cell motility, providing a mechanistic framework for cancer research focused on Barrett’s esophagus progression.

456 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page